{"entity":{"id":"nct06697301","kind":"trial","name":"Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma","aka":["TeLuRide-006"],"tldr":"A phase 2/3 trial testing EIK1001 in melanoma, now recruiting.","summary":"Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma is a phase 2/3 interventional study registered as NCT06697301, led by Eikon Therapeutics with Merck Sharp & Dohme, and recruiting on the registry. Official title: A Multicenter, Randomised, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006). Planned enrolment is 740 participants (estimated). The study started in 2025-05-22 and primary completion is expected in 2035-12. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06697301","url":"https://clinicaltrials.gov/study/NCT06697301"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","advanced-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["eik1001"],"companies":["eikon-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06697301","phase":"2/3","setting":"A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006)","sponsor":"Eikon Therapeutics","participation":[{"nct":"NCT06697301","source":"https://clinicaltrials.gov/study/NCT06697301","fetchedAt":"2026-10-07T16:54:56.691Z","studySha256":"177effd98e2f707533cb141412a9428655a153f36b0c4dcca1e3a916a84a2a1c","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Eikon Therapeutics","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":740,"enrolmentType":"ESTIMATED","siteCount":127,"recruitingSiteCount":125,"countries":["Australia","Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Hungary","Israel","Italy","New Zealand","Norway","Poland","Portugal","Serbia","South Africa","South Korea","Spain","Sweden","Switzerland","United Kingdom","United States"]}],"started":"2025-05-22","startedType":"actual","enrolled":740,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06697301/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"eik1001","kind":"drug","name":"EIK1001","route":"/drugs/eik1001/"}],"company":[{"id":"eikon-therapeutics","kind":"company","name":"Eikon Therapeutics","route":"/companies/eikon-therapeutics/"}]}}